Genmab A/S
Arzerra Second Quarter 2011 Net Sales Figures
Genmab A/S 26.07.2011 13:08 Dissemination of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- - Arzerra worldwide net sales in Q2 2011 totaled GBP 10.5 million (DKK 88.6 million) - Genmab expects royalty payment of DKK 17.7 million Copenhagen, Denmark; July 26, 2011 - Genmab A/S (OMX: GEN) announced today that the Arzerra(R) (ofatumumab) net sales during the second quarter of 2011 were GBP 10.5 million (approximately DKK 88.6 million). This figure consists of net sales in the U.S. of GBP 7.4 million (approximately DKK 62.4 million) and in the rest of the world GBP 3.1 million (approximately DKK 26.2 million). Under the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty payment of approximately DKK 17.7 million. The conversion from GBP to DKK has been made using the Danish Central Bank average rates for the second quarter of 2011 of GBP 1.00 = DKK 8.4474. About Genmab A/S Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company's first marketed antibody, Arzerra(R) (ofatumumab), was approved to treat refractory chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated and next generation antibody technologies are expected to provide a steady stream of future product candidates. Partnering of innovative product candidates and technologies is a key focus of Genmab's strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com. Contact: Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com This Company Announcement contains forward looking statements. The words 'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section 'Risk Management' in Genmab's Annual Report, which is available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law. Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-CD38(TM); HuMax-TF(TM); HuMax-Her2(TM); HuMax-cMet(TM), HuMax-CD74(TM), DuoBody(TM) and UniBody(R) are all trademarks of Genmab A/S. Arzerra(R) is a trademark of GlaxoSmithKline. Company Announcement no. 23 CVR no. 2102 3884 Genmab A/S Bredgade 34 1260 Copenhagen K Denmark 26.07.2011 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Genmab A/S Denmark Phone: Fax: E-mail: Internet: ISIN: DK0010272202 WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found